Key Factors Driving Market Growth:
The growth in 3D Cell Culture Market is primarily driven by the increasing focus on developing alternatives to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, the lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to limit market growth during the forecast period.
Expected Market Revenue Growth:
The 3D Cell Culture Market is projected to reach USD 1,846 million by 2024 from USD 892 million in 2019, at a CAGR of 15.7%.
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the 3d cell culture market. A detailed analysis of the key industry players has been done to provide insights into their business overviews; solutions and services; key strategies; new product launches; mergers; and partnerships, agreements, and collaborations; and recent developments associated with the market.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191072847
The cancer stem cell research segment is expected to grow at the highest CAGR during the forecast period
Based on application, the 3D cell culture market is segmented into cancer stem cell research, drug discovery toxicology testing, and tissue engineering regenerative medicine. The cancer stem cell research segment accounted for the largest share of the market in 2018 and is expected to register the highest CAGR during the forecast period. The increasing prevalence of cancer and significant funding for cancer research are major factors driving the growth of this application segment.
"Based on end user, the pharmaceutical biotechnology companies segment is projected to grow at the highest CAGR during the forecast period."
Based on end user, the market is segmented into pharmaceutical biotechnology companies, research institutes, the cosmetics industry, and other end users. In 2018, the pharmaceutical biotechnology companies segment accounted for the largest share of the 3D Cell Culture Market share. This segment is also projected to grow at the highest CAGR in the forecast period. Strong manufacturing and RD activity in pharmaceutical biotechnology companies, the increasing RD expenditure, and growing focus on alternatives to animal testing models are the key factors driving the growth of this segment.
"North America dominates the global 3D Cell Culture Market."
Based on region, the Cancer Therapeutics Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America commanded the largest share of the market. The increasing incidence of cancer and the presence of a well-established pharmaceutical biotechnology industry are some of the key factors supporting the growth of the North American market.
The 3D Cell Culture Market is marked by the presence of several big and small players. Some of the prominent players offering 3D cell culture products include Thermo Fisher Scientific (US), Corning Incorporated (US), Merck KGaA (Germany), Lonza AG (Switzerland), REPROCELL Incorporated (Japan), TissUse (Germany), InSphero (Switzerland), Synthecon (US), 3D Biotek (US), CN Bio (UK), Hamilton Company (US), MIMETAS (Netherlands), Emulate (US), HìREL Corporation (US), QGel SA (Switzerland), SynVivo (US), Advanced BioMatrix (US), Greiner Bio-One International (Austria), and PromoCell (Germany).
Request For Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=191072847
These players adopted various growth strategies, such as product launches upgrades, expansions, acquisitions, partnerships, agreements, and collaborations to further expand their presence in the Cancer Therapeutics Market.
Thermo Fisher Scientific dominated the 3D cell culture market in 2018. The company’s leading position can be attributed to its strong brand image and robust product portfolio. The company has a strong foothold in the market with its established brand AlgiMatrix. The company focuses on RD activities and product launches to further strengthen its position in the market. In 2018, the company invested USD 967 million in RD activities. It also adopts organic and inorganic growth strategies such as expansions and acquisitions in order to maintain its position in Cancer Therapeutics Market.
